{"title":"精神分裂症精神药物治疗的未来：更多的非典型抗精神病药物？猜猜看","authors":"Ahmed Naguy, Saxby Pridmore, Bibi Alamiri","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>No single neurotransmitter aberration could explain the heterogeneity of schizophrenia syndrome and thus, treatment strategies capitalizing solely on a single neurotransmitter system (e.g., DA blockade) is less likely to be fully successful on clinical grounds. Hence, there is a pressing need to develop <i>newer</i> antipsychotics above and beyond DA antagonism. In this regard, authors brief on <i>five</i> agents that sound pretty promising and might usher in a new sparkle in the psychopharmacotherapy of schizophrenia. This paper is a sequel for authors' previous article on future of schizophrenia psychopharmacotherapy.</p>","PeriodicalId":21069,"journal":{"name":"Psychopharmacology bulletin","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981338/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>The Future of Schizophrenia Psychopharmacotherapy</i>: More Antipsychotic Atypicality? Guess So!\",\"authors\":\"Ahmed Naguy, Saxby Pridmore, Bibi Alamiri\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>No single neurotransmitter aberration could explain the heterogeneity of schizophrenia syndrome and thus, treatment strategies capitalizing solely on a single neurotransmitter system (e.g., DA blockade) is less likely to be fully successful on clinical grounds. Hence, there is a pressing need to develop <i>newer</i> antipsychotics above and beyond DA antagonism. In this regard, authors brief on <i>five</i> agents that sound pretty promising and might usher in a new sparkle in the psychopharmacotherapy of schizophrenia. This paper is a sequel for authors' previous article on future of schizophrenia psychopharmacotherapy.</p>\",\"PeriodicalId\":21069,\"journal\":{\"name\":\"Psychopharmacology bulletin\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981338/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
没有一种单一的神经递质畸变可以解释精神分裂症综合征的异质性，因此，仅利用单一神经递质系统（如 DA 阻断）的治疗策略不太可能在临床上取得完全成功。因此，亟需开发出DA拮抗之外的新型抗精神病药物。在这方面，作者简要介绍了五种听起来很有前景的药物，它们可能会为精神分裂症的精神药物治疗带来新的火花。本文是作者上一篇关于精神分裂症精神药物疗法未来的文章的续篇。
The Future of Schizophrenia Psychopharmacotherapy: More Antipsychotic Atypicality? Guess So!
No single neurotransmitter aberration could explain the heterogeneity of schizophrenia syndrome and thus, treatment strategies capitalizing solely on a single neurotransmitter system (e.g., DA blockade) is less likely to be fully successful on clinical grounds. Hence, there is a pressing need to develop newer antipsychotics above and beyond DA antagonism. In this regard, authors brief on five agents that sound pretty promising and might usher in a new sparkle in the psychopharmacotherapy of schizophrenia. This paper is a sequel for authors' previous article on future of schizophrenia psychopharmacotherapy.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
